133 related articles for article (PubMed ID: 35382842)
1. DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228.
Fiorentino F; Krell J; de la Rosa CN; Webber L
Trials; 2022 Apr; 23(1):261. PubMed ID: 35382842
[TBL] [Abstract][Full Text] [Related]
2. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
4. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
5. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
7. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
10. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
11. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S; Giannone G; Clamp AR; Ennis DP; Glasspool RM; Herbertson R; Krell J; Riisnaes R; Mirza HB; Cheng Z; McDermott J; Green C; Kristeleit RS; George A; Gourley C; Lewsley LA; Rai D; Banerji U; Hinsley S; McNeish IA
JAMA Oncol; 2023 May; 9(5):675-682. PubMed ID: 36928279
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
14. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
15. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study.
Chen T; Xu J; Xia B; Wang H; Shen Y
J Gynecol Oncol; 2024 Jan; 35(1):e22. PubMed ID: 37945326
[TBL] [Abstract][Full Text] [Related]
18. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
